The Analgesic Efficacy of Magnesium and Ketorolac in Ultrasound Supraclavicular Block

Sponsor
Fayoum University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04554862
Collaborator
(none)
80
1
2
14
5.7

Study Details

Study Description

Brief Summary

Despite many regional anesthetic techniques have been described for anesthesia of the brachial plexus which is responsible for the sensory and motor innervation of entire upper limb, still, supraclavicular block (SCB) is the regional anesthetic technique of choice.

SCB has been described as the spinal anesthesia of the upper limb as it offers dense anesthesia of the brachial plexus for the surgical procedures below the arm from elbow to hand. Although the SCB has a high incidence of complications like pneumothorax, the use of ultrasound-guided block improved the safety for the patient. There are several adjuvants have been added to SCB aiming for prolongation of the duration of peripheral nerve block as fentanyl, alpha 2 adrenergic agonist (Dexmedetomidine, Clonidine), tramadol, ketorolac and Magnesium sulfate.

Magnesium has anti-nociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells. Calcium influx leads to a sequence of central sensitization such as windup phenomenon and long term potentiation which are crucial mechanisms that determine the duration and intensity of post-operative pain. Magnesium prevents central sensitization triggered by peripheral nociceptive stimulation in response to painful stimuli.

Non-Steroidal Anti-Inflammatory drugs (NSAID) inhibit synthesis of prostaglandins from arachnoid acid in phospholipid membranes resulting in decreased afferent nociceptive signals from the site of surgery. There are a lot of studies supported the analgesic effect when NSAIDs are concentrated at a peripheral site compared to the systemic administration therapy. Ketorolac is a parenteral NSAIDs. Studies have shown that ketorolac as an adjuvant to local anesthetics during peripheral nerve block enhanced duration and quality of analgesia.

Condition or Disease Intervention/Treatment Phase
  • Drug: Magnesium sulfate
  • Drug: Ketorolac Tromethamine
  • Procedure: supraclavicular block
Phase 4

Detailed Description

Eighty adult patients scheduled for upper limb surgeries from elbow to hand will be enrolled in the study after obtaining approval of the local institutional ethics committee and local institutional review board at Fayoum University Hospital. A detailed informed consent will be signed by the eligible participants before recruitment and randomization.

80 patients will be chosen to receive either Mg (group M, n=40) or ketorolac (group K, n=40) randomly by a computer-generated table. The randomization sequence will be concealed in opaque sealed envelopes. The envelopes will be opened by the study investigator just after recruitments and admission to the operation room. Only participants and care providers will be blinded to the group allocations. The consolidated standards of reporting trials (CONSORT) recommendations for reporting randomized, controlled clinical trials will be followed.

Patient preoperative preparations:

Preoperative investigations will be done according to the local protocol designed to evaluate the patients. It will include complete blood count, blood sugar level, serum urea and creatinine, liver function tests, coagulation profile, and ECG.

Before surgery, the participants will receive education about the (NRS) from (0-10 mm) (where 0=no pain and 10 = worst comprehensible pain) and the details of the nerve block procedures.

After a 6h fasting, the patients will be taken to the operating theatre.

Anesthetic technique:

A (20G) IV catheter will be placed in the UL opposite the surgical site after the arrival of the patient to the operating room. IV premedication will be administered to all patients (midazolam 0.02mg/kg and fentanyl 50mcg/dose). Supplemental oxygen (nasal cannula at 2L/min), and standard ASA monitoring (5-lead ECG, NIBP, and pulse oximetry) will be applied throughout the procedure.

Block technique

For the ultrasound-guided SCB, the patients will be placed in a supine position and the head turned slightly to the opposite side of their block. The injured hand will be put on the patient's abdomen and the shoulder will be moved downward as much as possible. The supraclavicular area will be cleaned using an antiseptic iodine solution and draped. Once the skin will be appropriately cleaned and prepared with anti-septic, the high-frequency linear array transducer will be placed over the supraclavicular area. After infiltration of the site by a local anesthetic, a sterile 22 gauge, 50 mm echogenic needle under ultrasound guidance will be inserted and after reaching the tip of the needle near the subclavian artery around the brachial plexus, the solution will be injected and the spread of the drug will be visualized. 25 ml of bupivacaine 0.5% + 6ml of magnesium sulfate 10% will be injected to group M and 25ml of bupivacaine 0.5% + 2ml of ketorolac 30mg + 4ml normal saline will injected to group K. The continuous aspiration and injection will be taken to avoid intravascular injection. After performing the block on the patients, hemodynamic parameters and all complications related to SCB (pneumothorax, hematoma, hypotension, bradycardia, etc.) will be recorded. After ensuring adequate anesthetic effect of the block, the surgery was started.

Assessment of sensory and motor blockade:

The extent of motor and sensory blockade will be evaluated by an anesthesiologist who will not be involved in the SCB 30 minutes. after local anesthetic administration. Using an alcohol swab, the sensory blockade will be tested by pin prick test using a 3- point scale:

Grade 0: normal sensation. Grade 1: decreased pain sensation to pinprick. Grade 2: loss of pain sensation to pinprick in the median, ulnar, radial and musculocutaneous nerve locations.

And it will be tested every 5 minutes for 30 minutes.

Motor blockade will be assessed by using (modified bromage) 3-point scale:

Grade 0: Normal motor function. Grade 1: Decreased motor strength with ability to move fingers only. Grade 2: Complete motor block. And it will be tested every 5 minutes for 30 minutes. When the operation was over, NRS score will be measured at 0, 1, 4, 8, 12, 24 hours.

Post-operative care:

Patients will be transferred to post-anesthetic care unit (PACU) for 2 hours. Then the patients will be discharged from the PACU.

Patient will receive analgesic according to the local institutional protocol as the following (Diclofenac sodium 75mg and paracetamol 1 gram by intravenous infusion over 30 minute.) as a component of multimodal anesthesia regimen for postoperative pain control.

Post-operative pain will be rated on (NRS) from 0 (no pain) to 10 (worst imaginable pain) at 1hr at PACU then at 4,8,12 and 24 hours postoperatively.

Patients with NRS>5 will receive morphine sulfate IV at a bolus dose of 2-5 mg increments with maximum dose of 20 mg at 4hours or 40mg at 24 hours. The morphine titration protocol will be suspended with Oxygen saturation < 95%; Respiratory rate < 10 / minute; the development of sedation (Ramsay sedation scale >2); development of acute adverse effects (allergy, marked itching, excessive vomiting, and hypotension with systolic blood pressure less than 20% of baseline values); or attaining adequate level of analgesia.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Prevention
Official Title:
The Analgesic Efficacy of Adding Magnesium Sulfate Versus Ketorolac to Bupivacaine in Ultrasound-guided Supraclavicular Brachial Plexus Block (A Prospective- Double-blinded Randomized Controlled Trial)
Actual Study Start Date :
Oct 1, 2019
Anticipated Primary Completion Date :
Nov 30, 2020
Anticipated Study Completion Date :
Nov 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: the intervention group (M) magnesium sulfate

a 6ml of magnesium sulfate 10% (600mg) will be added to 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block

Drug: Magnesium sulfate
magnesium sulfate will be added to the block
Other Names:
  • magnesium 10%
  • Procedure: supraclavicular block
    it is done by ultrasound- guided

    Active Comparator: the intervention group (K) ketorolac

    a 2ml of ketorolac (30mg) will be added to 4ml of normal saline and 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block

    Drug: Ketorolac Tromethamine
    ketorolac will be added to the block
    Other Names:
  • ketorolac
  • Procedure: supraclavicular block
    it is done by ultrasound- guided

    Outcome Measures

    Primary Outcome Measures

    1. the cumulative morphine consumption [At 24 hours postoperative]

      In milligrams

    Secondary Outcome Measures

    1. numerical rating scale (NRS) of postoperative pain [at 1 hour in the post-anesthesia care unit (PACU)]

      the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)

    2. numerical rating scale (NRS) of postoperative pain [at 4 hours postoperative]

      the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)

    3. numerical rating scale (NRS) of postoperative pain [at 8 hours postoperative]

      the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)

    4. numerical rating scale (NRS) of postoperative pain [at 12 hours postoperative]

      the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)

    5. numerical rating scale (NRS) of postoperative pain [at 24 hours postoperative]

      the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)

    6. incidence of opioid related side-effects [5 minutes after supraclavicular block till discharge from PACU]

      side effects (nausea, vomiting, pruritus, excessive sedation, and respiratory depression)

    7. incidence of adverse effects related to the block [5 minutes after supraclavicular block till discharge from PACU]

      adverse events (e.g. vascular puncture, local anesthetic toxicity, and pneumothorax)

    8. time to the first requirement of analgesic supplement [5 minutes After supraclavicular block till first requirement of analgesic]

      In minutes

    9. Duration of surgical procedures [5 minutes after completion of surgical procedures]

      In minutes

    10. Assessment of heart rate [from the start of the block till completion of surgical procedures]

      In beats per minutes

    11. Assessment of mean blood pressure [from the start of the block till completion of surgical procedures]

      In millimetre mercury (mmHg)

    12. Assessment of respiratory rate [from the start of the block till completion of surgical procedures]

      Number of breaths per minute

    13. Assessment of Oxygen saturation [from the start of the block till completion of surgical procedures]

      In percentage through use of pulse oximetry

    14. Age [10 minutes before surgery]

      in years

    15. Weight [10 minutes before surgery]

      in kilograms (kg)

    16. Height [10 minutes before surgery]

      in meters (m)

    17. Body mass index [10 minutes before surgery]

      in kg/m square

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • American Society of Anesthesiologists (ASA) physical status from I to III participants who were scheduled for surgical procedures of the arm from elbow to hand
    Exclusion Criteria:
    • Patient refusal.

    • Contraindication to regional anesthesia (coagulopathy, allergy to the local anesthetic or any adjuvants added, severe thrombocytopenia, pre-existing neuropathy in the operative limb, infection at puncture site).

    • Sepsis.

    • Pregnant or lactating women.

    • Hepatic or renal dysfunction.

    • Any drug or opioid abuse.

    • Surgical procedures for more than 3h.

    • Advanced cardiac diseases.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Fayoum University hospital Madīnat Al Fayyūm Faiyum Governorate Egypt 63514

    Sponsors and Collaborators

    • Fayoum University Hospital

    Investigators

    • Principal Investigator: Safaa G Ragab, MD, Faculty of medicine, Fayoum university

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Safaa Gaber Ragab, Lecturer of anesthesiology, Fayoum University Hospital
    ClinicalTrials.gov Identifier:
    NCT04554862
    Other Study ID Numbers:
    • M419
    First Posted:
    Sep 18, 2020
    Last Update Posted:
    Sep 18, 2020
    Last Verified:
    Sep 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Safaa Gaber Ragab, Lecturer of anesthesiology, Fayoum University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 18, 2020